loading page

Non-bullous pemphigoid associated with immune checkpoint inhibitor treatment
  • +3
  • Akiyoshi Senda,
  • Takaya Komori,
  • Yoshihiro Ishida,
  • Teruasa Murata,
  • Atsushi Otsuka,
  • Kenji Kabashima
Akiyoshi Senda
Kyoto University Graduate School of Medicine Faculty of Medicine

Corresponding Author:[email protected]

Author Profile
Takaya Komori
Kyoto University Graduate School of Medicine Faculty of Medicine
Author Profile
Yoshihiro Ishida
Kyoto University Graduate School of Medicine Faculty of Medicine
Author Profile
Teruasa Murata
Kyoto University Graduate School of Medicine Faculty of Medicine
Author Profile
Atsushi Otsuka
Kyoto University
Author Profile
Kenji Kabashima
Kyoto University
Author Profile

Abstract

Though a variety of immune-related adverse events of immune checkpoint inhibitors (ICIs) including bullous pemphigoid have been reported, non-bullous pemphigoid (NBP) associated with ICI therapy was scarcely reported. We present a case of NBP with a long latent disease course without diagnosis during nivolumab, an ICI therapy.